ArticleESMO open2022

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report.

M C Hardenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.